x

Posted 14 February, 2024

IMPEL PHARMACEUTICALS INC appointed new CEO

CEO Change detected for ticker OTC:IMPLQ in a 8-K filed on 14 February, 2024.


  In connection with the closing of the Asset Sale, Len Paolillo departed as the Company's Interim Chief Executive Officer on February 12, 2024.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of IMPEL PHARMACEUTICALS INC
Health Care/Life Sciences • Pharmaceuticals
Impel Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It engages in the development and commercialization of transformative therapies for patients suffering from diseases with high unmet medical needs with an initial focus on diseases of the central nervous system. The company was founded by Rodney J. Y. Ho, John D. Hoekman, and Michael P. Hite in 2008 and is headquartered in Seattle, WA.
Market Cap
$182K
View Company Details
IMPEL PHARMACEUTICALS INC by TradingView
Relevant filing section
Item 5.02 Departure of Directors and Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

In connection with the closing of the Asset Sale, Len Paolillo departed as the Company's Interim Chief Executive Officer on February 12, 2024. In connection with his resignation, Mr. Paolillo entered into a consulting agreement with the Company, effective as of February 13, 2024 (the "Consulting Agreement"), pursuant to which Mr. Paolillo will assist with the transition of his role and provide advisory services to the Company through June 30, 2024 (such period, the "Consulting Period"). Pursuant to the terms of the Consulting Agreement, Mr. Paolillo will be entitled to a consulting rate of $500.00 per hour during the Consulting Period.